Related Experiment Video

Updated: Jan 8, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K

A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK-β

Fan Luo1, Ting Yang2, Jiaxin Cao3

  • 1Department of Intensive Care Unit, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|December 17, 2025
PubMed

Insights

The ubiquitin-editing enzyme A20 is crucial for regulating oxaliplatin resistance in colorectal cancer (CRC). Lower A20 expression correlates with poorer survival and chemoresistance by stabilizing IKK-β, impacting NF-κB activity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • A20 is vital for inflammatory homeostasis but its role in chemoresistance is unclear.
  • Understanding A20's function in oxaliplatin resistance is critical for colorectal cancer (CRC) treatment.

Purpose of the Study:

  • To investigate the mechanism by which A20 regulates oxaliplatin resistance in CRC.
  • To examine the role of A20-mediated IKK-β monoubiquitylation at K163 in this process.

Main Methods:

  • A prospective, randomized Phase III study comparing oxaliplatin-based neoadjuvant chemoradiotherapy (NACRT) with capecitabine-only NACRT in locally advanced CRC patients.
  • Immunohistochemistry analysis of preoperative and surgical specimens to assess A20 expression and its correlation with treatment response and survival.
  • In vivo studies using mouse xenografts to evaluate the impact of A20 knockdown or IKK-β K163R mutant expression on oxaliplatin resistance.

Main Results:

  • Lower A20 expression was observed in patients achieving pathological complete response (pCR) in the oxaliplatin-NACRT group, correlating with oxaliplatin resistance.
  • A20 downregulation in human CRC tissues was confirmed in independent cohorts, associated with poorer survival and chemoresistance.
  • Mechanistically, A20 monoubiquitylates IKK-β at K163, promoting its degradation and inhibiting NF-κB nuclear translocation; A20 depletion stabilizes IKK-β, inducing oxaliplatin resistance.

Conclusions:

  • The A20-IKK-β axis plays an essential role in mediating oxaliplatin resistance in colorectal cancer.
  • A20 functions as a tumor suppressor in CRC by inhibiting IKK-β stabilization and subsequent NF-κB activation, thereby sensitizing cancer cells to oxaliplatin treatment.
Keywords:
A20IKK‐βchemoresistancecolorectal canceroxaliplatin

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K
Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

3.0K

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
424
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.3K